Abbott Laboratories
NYSEABT has added another layer to its already constructive setup: a fresh target raise from a bellwether name, a stock now up 12% over the past month, and short sellers continuing to exit a name that has given them little reason to stay. The headline development since last week's note is TD Cowen lifting its price target on ABT to $135 from $115 on August 25, while…
ABT cost to borrow surges 382.6% over one week to 0.39%, signaling tightening share availability for short sellers despite minimal short interest at 1.4% of float.
A new long-form analysis for ABT this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumABT has added another layer to its already constructive setup: a fresh target raise from a bellwether name, a stock now up 12% over the past month, and short sellers continuing to exit a name that has given them little…
Snapshot as of 23 Sept 2026
ABT enters the final stretch of summer with a rare alignment of signals: a fresh analyst upgrade, a stock up 12% over the past month, and options traders at their most bullish in a year. The most telling move of the…
Abbott Laboratories reports Q2 results today having lost ground sharply since the prior earnings preview, with the stock sliding 6.2% over the past week to $89.27 — a notably weaker entry point than the $93.93 level…
Abbott Laboratories heads into its July 15 Q2 print with a Street that remains broadly positive but has quietly trimmed expectations since the last report. The options market is sending a calm signal ahead of the…
ABT heads into its July 15 Q2 print with a fresh analyst initiation, options traders at their least defensive posture in twelve months, and a stock that gave back 2.1% on Tuesday to close at $90.74 — still well below…
ABT heads into its July 15 earnings date with a notable insider buying cluster and analysts anchored above the current price — even as the stock trades well below pre-April levels. The most interesting signal this week…
Abbott Laboratories enters the week with its options market sending the most bullish signal in twelve months — even as the stock drifts near its monthly lows and the broader medical-device peer group sells off…
Abbott Laboratories is down nearly 5% over the past month to $86.67, but company insiders and the Street's bulls are treating the decline as an entry point — even as the options market quietly rotates more bullish than…
Options traders have turned their most bullish in a year on ABT. The put/call ratio hit 0.71 on May 12 — a 52-week low — falling 2.16 standard deviations below its 20-day mean of 0.88. That's the sharpest swing toward…
ABT heads into the back half of April with insiders putting money to work at a stock that has fallen nearly 26% year-to-date — even as a wave of analyst target cuts follows the company's Q1 earnings miss. The most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ABT — free to start on ORTEX.
Sign up for free →Open ABT on ORTEX